Rochelle Bagatell

Also affiliated with University of Pennsylvania, Philadelphia University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 26 papers. Top paper: “KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group”.

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-006530

N/A

0.601DataRank · unranked

17 citations

Mitch B Diccianni, Rajen Mody, Arlene Naranjo, Fan F. Zhang, Jen Birstler +15 more

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors

Pediatric Blood & Cancer(2021)10.1002/pbc.29282

N/A

0.461DataRank · unranked

10 citations

Brigitte C. Widemann, Pamela S. Hinds, Rochelle Bagatell, Suzanne Shusterman, Emily Stern +12 more

Novel ATXN1/ATXN1L::NUTM2A fusions identified in aggressive infant sarcomas with gene expression and methylation patterns similar to CIC-rearranged sarcoma

Acta Neuropathologica Communications(2022)10.1186/s40478-022-01401-z

N/A

0.396DataRank · unranked

13 citations

Angela N. Viaene, Jenny Ruiz, Jeffrey Schubert, Jinhua Wu, Jiani Chen +16 more

Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi‐site longitudinal survey study

Cancer(2023)10.1002/cncr.35149

N/A

0.360DataRank · unranked

10 citations

Jesse Smith, Yiwang Zhou, Rochelle Bagatell, Justin N. Baker, Susan L. Cohn +10 more

Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10523

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Wendy B. London, Sheena C. Tenney +11 more

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3909

N/A

0DataRank · unranked

216 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.006

N/A

0DataRank · unranked

33 citations

Arlene Naranjo, Rochelle Bagatell, Steven G. DuBois, Jeannine S. McCune, Sheena C. Tenney +17 more

Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease

Cancer(2022)10.1002/cncr.34263

N/A

0DataRank · unranked

13 citations

Mark A. Applebaum, Theodore Karrison, Akosua Y. Oppong, Cindy Yuan, Katherine R. Berg +14 more

Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Children’s Oncology Group.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10027

N/A

0DataRank · unranked

0 citations

Marguerite T. Parisi, Barry L. Shulkin, Brian LaBarre, Rochelle Bagatell, Lisa Diller +9 more

Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group

Pediatric Blood & Cancer(2023)10.1002/pbc.30418

N/A

0DataRank · unranked

10 citations

Marguerite T. Parisi, Barry L. Shulkin, Brian LaBarre, Rochelle Bagatell, Lisa Diller +9 more

SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11519

N/A

0DataRank · unranked

14 citations

Karla V. Ballman, Rachel S. Heise, John Glod, Mary Frances Wedekind, Leo Mascarenhas +15 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294.v1

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531

Journal of Pediatric Surgery(2024)10.1016/j.jpedsurg.2024.161896

N/A

0DataRank · unranked

6 citations

E. Stanton Adkins, Peter Mattei, Fredric A. Hoffer, Sandra L. Wootton‐Gorges, Wendy B. London +14 more

A subset of image‐defined risk factors predict completeness of resection in children with high‐risk neuroblastoma: An international multicenter study

Pediatric Blood & Cancer(2024)10.1002/pbc.31218

N/A

0DataRank · unranked

6 citations

Rochelle Bagatell, Kieran McHugh, Arlene Naranjo, Collin Van Ryn, Yesenia Rojas +20 more

Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field

Radiotherapy and Oncology(2024)10.1016/j.radonc.2024.110384

N/A

0DataRank · unranked

4 citations

S. Shaaban, Jie Jane Chen, Rochelle Bagatell, Benjamin Lerman, Paul J. Catalano +20 more

Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531

Pediatric Blood & Cancer(2024)10.1002/pbc.31407

N/A

0DataRank · unranked

1 citations

Howard M. Katzenstein, Arlene Naranjo, Sheena C. Tenney, Lulu Chen, Wendy B. London +11 more

SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.11508

N/A

0DataRank · unranked

13 citations

Karla V. Ballman, Rachel S. Heise, Leo Mascarenhas, John Glod, Mary Frances Frances Wedekind +14 more

Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.10003

N/A

0DataRank · unranked

1 citations

Navin Pinto, Arlene Naranjo, Jed G. Nuchtern, Edward F. Attiyeh, Rochelle Bagatell +12 more

Healthcare utilization disparities among children with high‐risk neuroblastoma treated on Children's Oncology Group clinical trials

Pediatric Blood & Cancer(2024)10.1002/pbc.31192

N/A

0DataRank · unranked

0 citations

Yimei Li, Kelly Getz, Yuan‐Shung Huang, Matt Hall, Arlene Naranjo +12 more

Chromosomal instability degrades developmental phenotypes essential for anti-GD2 immunotherapy outcomes in high-risk neuroblastoma

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102375

N/A

0DataRank · unranked

3 citations

Jae Eun Choi, Calvin Hesse, Noshad Hosseini, Alec Chu, Jin Zhou +12 more

Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort study

Cancer(2020)10.1002/cncr.32947

N/A

0DataRank · unranked

18 citations

Evelyn Stevens, James Sharpe, Lauren L. Hochman, Joseph G. Reiter, Shawna R. Calhoun +7 more

Induction Regimens in High‐Risk Neuroblastoma: Systematic Review of Response Rates and Toxicities

Cancer Medicine(2025)10.1002/cam4.71312

N/A

0DataRank · unranked

0 citations

Eva C. Robinson, Edie Weller, Rochelle Bagatell, Lucas Moreno, Steven G. DuBois +1 more

Trends in conditional survival and predictors of late death in neuroblastoma

Pediatric Blood & Cancer(2020)10.1002/pbc.28329

N/A

0DataRank · unranked

9 citations

Kevin Campbell, Rochelle Bagatell, Steven G. DuBois, Hannah E. Olsen

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group

European Journal of Cancer(2020)10.1016/j.ejca.2020.04.007

N/A

0DataRank · unranked

31 citations

Arlene Naranjo, Emily Hibbitts, Julie M. Gastier‐Foster, Rochelle Bagatell, Meredith S. Irwin +5 more

Trends in conditional survival and predictors of late death in neuroblastoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10533

N/A

0DataRank · unranked

2 citations

Kevin Campbell, Rochelle Bagatell, Steven G. DuBois, Hannah E. Olsen